Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.75 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109715 | 1.00 | TLR8 (0.75) | TLR8TLR7NLRP3PIK3CAMTOR | |
| SCHEMBL18109611 | 0.97 | TLR8 (0.71) | TLR8TLR7NLRP3PIK3CA | |
| SCHEMBL18109614 | 0.97 | TLR8 (0.71) | TLR8TLR7NLRP3PIK3CA | |
| SCHEMBL18923203 | 0.90 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18125192 | 0.90 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18109289 | 0.89 | TLR8 (0.74) | TLR8TLR7NLRP3 | |
| SCHEMBL19940969 | 0.89 | TLR8 (0.60) | TLR8TLR7NLRP3 | |
| SCHEMBL19940722 | 0.89 | TLR8 (0.60) | TLR8TLR7NLRP3 | |
| SCHEMBL18109286 | 0.89 | TLR8 (0.74) | TLR8TLR7NLRP3 | |
| SCHEMBL19991825 | 0.89 | TLR8 (0.59) | TLR8TLR7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017048727-A1 | MODULATORS OF TOLL-LIKE RECPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3097102-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885NLRP3 49/4885 |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | TLR8 1416/4885TLR7 1621/4885NLRP3 2029/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | TLR8 1416/4885TLR7 1621/4885NLRP3 2029/4885 |
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | TLR8 4337/4885TLR7 3565/4885NLRP3 4620/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885NLRP3 49/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | TLR8 4337/4885TLR7 3565/4885NLRP3 4620/4885 |
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | TLR8 3360/4885TLR7 2795/4885NLRP3 4133/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885NLRP3 49/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885NLRP3 49/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | TLR8 158/4885TLR7 60/4885NLRP3 464/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 4/4885NLRP3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.